Dupilumab‐related ocular surface disorders in a paediatric cohort with atopic dermatitis, treated in a tertiary paediatric hospital in London
Abstract Background Dupilumab is the first human monoclonal antibody approved for the treatment of moderate–severe atopic dermatitis (AD) in children from 6 years of age. Real‐world studies reviewing dupilumab‐related ocular surface disorders (DROSD) in the paediatric population are needed to detail...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley
2024-12-01
|
| Col·lecció: | JEADV Clinical Practice |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1002/jvc2.528 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|